LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $94.57 Average Price Target from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $94.57.

A number of research firms have weighed in on LMAT. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday. JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Lake Street Capital started coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. Oppenheimer restated an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Finally, Barrington Research lifted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st.

LeMaitre Vascular Stock Up 3.1 %

Shares of LMAT opened at $104.25 on Friday. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of 56.97, a PEG ratio of 2.49 and a beta of 0.89. LeMaitre Vascular has a 52 week low of $47.72 and a 52 week high of $104.81. The stock’s 50-day moving average price is $90.66 and its 200-day moving average price is $84.41.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.33 EPS. As a group, equities analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a $0.16 dividend. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.61%. LeMaitre Vascular’s payout ratio is currently 34.97%.

Insider Transactions at LeMaitre Vascular

In other news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Driehaus Capital Management LLC increased its position in LeMaitre Vascular by 52.2% during the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares during the last quarter. F M Investments LLC acquired a new position in shares of LeMaitre Vascular in the 2nd quarter valued at $7,443,000. Nicholas Investment Partners LP purchased a new position in shares of LeMaitre Vascular during the 2nd quarter worth $3,900,000. Janus Henderson Group PLC raised its holdings in LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after buying an additional 47,218 shares during the period. Finally, Vanguard Group Inc. lifted its position in LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.